Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.36 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117962 | 0.84 | KDM4E (0.40) | POLBGAAPDE10AEPHX2GPR6 | |
| SCHEMBL3121941 | 0.84 | KDM4E (0.40) | POLBGAAPDE10AEPHX2GPR6 | |
| SCHEMBL30505244 | 0.83 | EPHX2 (0.44) | POLBGAAPDE10AEPHX2GPR6 | |
| SCHEMBL23761235 | 0.83 | EPHX2 (0.44) | POLBGAAPDE10AEPHX2GPR6 | |
| SCHEMBL3128288 | 0.83 | GPR6 (0.42) | POLBGAAPDE10AEPHX2GPR6 | |
| Hydrochloric Acid SCHEMBL25401967 | 0.81 | EPHX2 (0.44) | POLBGAAPDE10AEPHX2GPR6 | |
| SCHEMBL6530291 | 0.80 | KDM4E (0.50) | POLBGAAEPHX2GPR6KDM4E | |
| SCHEMBL29844280 | 0.80 | KDM4E (0.47) | POLBGAAPDE10AEPHX2GPR6 | |
| SCHEMBL17202505 | 0.79 | POLB (0.41) | POLBGAAPDE10AEPHX2GPR6 | |
| SCHEMBL19527606 | 0.77 | GAA (0.40) | POLBGAAPDE10AEPHX2GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | POLB 4292/4885GAA 3193/4885PDE10A 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.